Everolimus 'not recommended' in adjuvant early breast cancer setting - medwireNews

The addition of everolimus to standard adjuvant endocrine therapy does not improve the outcomes of women with hormone receptor-positive, HER2-negative early breast cancer at high risk for recurrence, show phase 3 trial results.

medwireNews: The addition of everolimus to standard adjuvant endocrine therapy (ET) does not improve the outcomes of women with hormone receptor-positive, HER2-negative early breast cancer at high ri… [+1654 chars]

full article...